ARTARA THERAPEUTICS INC TARA 深 滬
交易中 09-17 11:37:48 美东时间
3.07
0.000
0.00%
華盛通- 最 高3.10
- 今 開3.07
- 成交量 1.49万股
- 最 低 3.061
- 昨 收 3.07
- 總市值 1.18亿
- 52周最高 10.48
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 1.595
- 委 比 -67.23%
- 總股本 3858.19万
- 歷史最高 800.00
- 量 比 0.39
- 振 幅 1.27%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Analysts Offer Insights on Healthcare Companies: Amicus (FOLD) and Protara Therapeutics (TARA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
今天 16:50
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq...
09-03 04:05
快讯 | Protara Therapeutics, Inc.报告了根据纳斯达克上市规则5635(C)(4)的诱导授予
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule ...
09-03 04:05
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics announced that its management will participate in two investor conferences: the Cantor Global Healthcare Conference on September 4, 2025, featuring a fireside chat, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a corporate presentation. Details and live webcasts can be accessed via the company's website. Protara focuses on developing therapies for cancer and rare diseases, with it...
08-27 12:00
Protara Therapeutics Q2 EPS $(0.35) Beats $(0.41) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 13.58 percent. This is a 22.22 percent increase over losses of $(0.45) per share
08-11 20:15
快讯 | Protara Therapeutics 公布 2025 年第二季度财务业绩并提供业务更新
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provid...
08-11 20:00
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics granted stock options and RSUs to two new hires, totaling 29,500 options and 14,750 RSUs under its Inducement Plan. The options have an exercise price of $2.80 and vest over four years, while RSUs vest over three years. The company, focused on cancer and rare disease therapies, recently announced these awards to attract and retain key talent, aligned with Nasdaq Listing Rule 5635(c)(4).
07-01 20:12
Protara Therapeutics Announces Addition to the Russell 3000® Index
Protara Therapeutics, Inc. has been added to the Russell 3000® Index, reflecting its progress in advancing therapies for cancer and rare diseases, including clinical trials for TARA-002 and its IV Choline Chloride program. The inclusion enhances the company's visibility among investors.
06-30 12:00
快讯 | Protara Therapeutics 宣布任命威廉·孔克林为首席商务官
Protara Therapeutics Announces Appointment of William Conkling as Chief Commerc...
06-03 04:04
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
Protara Therapeutics appointed William “Bill” Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapies. Conkling previously led the successful launch of Trodelvy at Immunomedics and managed Kymriah at Novartis. Jesse Shefferman, CEO of Protara, highlighted Conkling’s expertise in building commercial organizations and expressed confidence in the company’s tran...
06-02 20:04
